It depends. Sometimes it&#x27;s simply more profitable to produce something else. Sometimes the market is too small to justify the bioequivalence studies. Sometimes the FDA mysteriously changes its mind on the safety of a drug the same day the patent expires [1].<p>[1] <a href="http:&#x2F;&#x2F;www.npr.org&#x2F;sections&#x2F;health-shots&#x2F;2013&#x2F;04&#x2F;17&#x2F;177602393&#x2F;why-fdas-rejection-generic-oxycontin-may-have-side-effects" rel="nofollow">http:&#x2F;&#x2F;www.npr.org&#x2F;sections&#x2F;health-shots&#x2F;2013&#x2F;04&#x2F;17&#x2F;17760239...</a>